AGC Biologics’ Seattle Site
AGC Inc. (Tokyo; www.agc.com) announced a major expansion of AGC Biologics, a U.S>-based subsidiary of the company. At AGC Biologics’ Seattle site, plans have been finalized to install twelve additional 2,000-L single-use mammalian-cell bioreactors, and to establish a brand new microbial contract development and manufacturing facility. AGC Biologics’ current microbial capacities are in Europe and Japan, and the addition of the Seattle facility will provide wider regional coverage across the continents for microbial services as well. Once operational, AGC’s biopharmaceutical production capacity in the U.S. will be tripled. The total investment for this expansion is estimated to be about 10 billion yen, with full-scale operations slated to start from July 2020.